234 related articles for article (PubMed ID: 30833442)
1. A cohort study of hypersensitivity reaction in patients with epithelial ovarian cancer treated with carboplatin.
Sun T; Li L
Int J Gynecol Cancer; 2019 Mar; 29(3):566-571. PubMed ID: 30833442
[TBL] [Abstract][Full Text] [Related]
2. [Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].
Li L; Wu M; Yang JX; Wan XR; Huang HF; Pan LY; Shen K; Lang JH; Xiang Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):825-831. PubMed ID: 27916065
[No Abstract] [Full Text] [Related]
3. Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
Jerzak KJ; Deghan Manshadi S; Ng P; Maganti M; McCuaig JM; Bulter M; Oza A; Mackay HJ
J Oncol Pharm Pract; 2018 Mar; 24(2):83-90. PubMed ID: 27856924
[TBL] [Abstract][Full Text] [Related]
4. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.
Polyzos A; Tsavaris N; Kosmas C; Arnaouti T; Kalahanis N; Tsigris C; Giannopoulos A; Karatzas G; Giannikos L; Sfikakis PP
Oncology; 2001; 61(2):129-33. PubMed ID: 11528251
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
6. Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.
Dizon DS; Dupont J; Anderson S; Sabbatini P; Hummer A; Aghajanian C; Spriggs D
Gynecol Oncol; 2003 Dec; 91(3):584-90. PubMed ID: 14675681
[TBL] [Abstract][Full Text] [Related]
7. [Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Zheng H; Gao YN; Jiang GQ; Gao M; Wang W; Yan X
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):839-42. PubMed ID: 19087568
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for and prognosis of carboplatin-related hypersensitivity in patients with epithelial ovarian cancer.
Hwang WY; Lee M; Suh DH; Kim K; No JH; Kim YB; Kim JH
Arch Gynecol Obstet; 2022 Aug; 306(2):443-449. PubMed ID: 35044514
[TBL] [Abstract][Full Text] [Related]
9. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
Sivakumaran T; Mileshkin L; Grant P; Na L; DeFazio A; Friedlander M; Obermair A; Webb PM; Au-Yeung G;
Gynecol Oncol; 2020 Jul; 158(1):47-53. PubMed ID: 32381362
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
Bergamini A; Pisano C; Di Napoli M; Arenare L; Della Pepa C; Tambaro R; Facchini G; Gargiulo P; Rossetti S; Mangili G; Pignata S; Cecere SC
Gynecol Oncol; 2017 Jan; 144(1):72-76. PubMed ID: 28094039
[TBL] [Abstract][Full Text] [Related]
12. Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
Konecny GE; Hendrickson AEW; Davidson TM; Winterhoff BJ; Ma S; Mahner S; Sehouli J; Fasching PA; Feisel-Schwickardi G; Poelcher M; Roman LD; Rody A; Karlan BY; Mullany SA; Chen H; Ray-Coquard IL; Provencher DM; Yachnin A; Cottu PH; Glaspy JA; Haluska P; Slamon DJ
Gynecol Oncol; 2021 Dec; 163(3):465-472. PubMed ID: 34642026
[TBL] [Abstract][Full Text] [Related]
13. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
15. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
[TBL] [Abstract][Full Text] [Related]
16. Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Kim SI; Lee EJ; Lee M; Chung H; Kim JW; Park NH; Song YS; Kim HS
Int J Gynecol Cancer; 2020 Dec; 30(12):1943-1950. PubMed ID: 33055266
[TBL] [Abstract][Full Text] [Related]
17. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study.
Vrdoljak J; Boban T; Petrić Miše B; Boraska Jelavić T; Bajić Ž; Tomić S; Vrdoljak E
Jpn J Clin Oncol; 2019 Apr; 49(4):347-353. PubMed ID: 30796833
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
20. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
